Biosimilar Analytics Draw More FDA Focus At Celltrion Inflectra Committee, But…
Executive Summary
Agency also spent lot of time assuring advisory committee members that some product differences are not as important as others.
You may also be interested in...
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
US FDA advisors overwhelming endorse Hospira's biosimilar referencing Amgen's Epogen, but still wanted broader immunogenicity data and postmarketing surveillance.
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
US FDA advisors overwhelming endorse Hospira's biosimilar referencing Amgen's Epogen, but still wanted broader immunogenicity data and postmarketing surveillance.
FDA In 2022: Califf Nominated To Retake Commissioner Role
Should Robert Califf gain a second term as US FDA commissioner, he likely will find that many of the issues demanding attention remain the same as when he left the agency five years ago, even though the names of the products now linked with them are different.